To understand the political peril Republicans confront in their effort to repeal and replace Obamacare, it is worth noting that many of the areas that gained the most coverage from Obamacare are the working-class districts carried by President Trump with the largest margins.
After bracing for the worst, pharmaceutical executives emerged from a White House meeting with newly installed President Donald J. Trump relatively unscathed. But they soon concluded that his ever-roving spotlight would be back on them in a matter of time.
Our new President seemed to criticize recent inversions, but more importantly vowed to go after the industry: “Our drug industry has been disastrous.
The Republican sweep in the 2016 elections hands the enormous power of the Center for Medicare and Medicaid Innovation (CMMI) to the Trump administration. What to do with this power?
The stunning Trump victory and the Republican hold in the Senate, giving the GOP full control over the executive and legislative branches, provides some breathing space for a pharmaceutical industry that increasingly felt under siege.
As the most bizarre and unpredictable election season draws to a close, scrutiny is turning to wikileaked emails among senior officials in the Clinton campaign licking their chops to take on the pharmaceutical industry, and healthcare policymaking by the executive branch.
Six years after the enactment of the Affordable Care Act (ACA), policymakers are just beginning to appreciate a little-known provision that essentially outsources Congress’ authority over Medicare to the executive branch.
There is growing chatter among congressional aides that the pharma industry should ante up some resources to help address some yet-unresolved healthcare issues.
In June, the Obama administration’s Office of the Actuary issued the Medicare Trustees report, which determined “The Hospital Trust Fund is not adequately financed over the next 10 years.” The trust fund will be depleted by 2028, two years earlier than last year’s estimate.
Even if we eliminated all use of antibiotics in animals and all unnecessary use in humans, we still are bound by a pathetic pipeline to combat what we’re facing now.
CMS has received dramatic and overwhelming rejection from Congress and stakeholders demanding the proposal be withdrawn or substantially modified.
Ubl talks about topics such as drug pricing, the industry’s approach to PBMs, and the political antipharmaceutical rhetoric.
If CMS wins this battle over physician-administered Part B drugs, it will be emboldened to pursue even more radical “demonstrations” in Medicare Part D.
Can The Medicare Program Benefit From Competitive Bidding?
Since enactment of Obamacare, Republicans had vowed to “repeal and replace” the law. What has happened to the “replace” part of the “repeal and replace” of Obamacare?